Taurolidine 2% Catheter Locking to Prevent Catheter-related Bloodstream Infections in Patients on Home Parenteral Nutrition With a High Infection Risk and Those With a New Central Venous Access Device

Trial Profile

Taurolidine 2% Catheter Locking to Prevent Catheter-related Bloodstream Infections in Patients on Home Parenteral Nutrition With a High Infection Risk and Those With a New Central Venous Access Device

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Taurolidine (Primary)
  • Indications Bacterial infections; Catheter infections; Septicaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jul 2018 Primary endpoint has not been met. (Mean number of catheter related blood stream infections CRBSI/1000 catheter days in preexisting catheter group)
    • 05 Jul 2018 Primary endpoint has been met. (Mean number of catheter related blood stream infections CRBSI/1000 catheter days in the new catheter group)
    • 05 Jul 2018 Results published in the Alimentary Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top